Stockreport

Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice

OptiNose, Inc.  (OPTN) 
Last optinose, inc. earnings: 3/5 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.optinose.com
PDF XHANCE significantly reduced both symptoms and sinus opacification in participants with chronic sinusitis (chronic rhinosinusitis) in two randomized controlled Phase 3 C [Read more]